Commentary
Video
Clinical Potential of Cognito’s Gamma Sensory Stimulation Device in Alzheimer Disease: Brent Vaughan
Author(s):
The chief executive officer of Cognito Therapeutics provided an in-depth overview of the company’s gamma sensory stimulation device, its mechanism of action, and why it serves as a promising therapy for patients with Alzheimer disease. [WATCH TIME: 5 minutes]
WATCH TIME: 5 minutes
"What we learned is that we’re able to use different frequencies of light and sound stimulation, we can activate the visual cortex, the auditory cortex, which map directly into the occipital and temporal regions of the brain."
Several in the field of Alzheimer disease (AD) believe the only way to effectively treat the disease will come through a variety of different therapeutic targets and mechanisms of action. While antiamyloid therapies have largely dominated the conversation, the 2023 Clinical Trials on Alzheimer’s Disease (CTAD) conference, held October 24-27, in Boston, Massachusetts, was a good reminder of the rich therapeutic pipeline of AD, currently filled with agents with different therapeutic potentials. One such therapy, Cognito’s gamma sensory stimulation device, continued to show promising benefits in its phase 2 OVERTURE study (NCT03556280), for which 18-month data was presented at the meeting.
In the open-label extension study, treatment with the therapy resulted in a mean total of 422.27 days to reach at least a 15% decline in Alzheimer’s Disease Cooperative Study-Activities of Daily Living total score vs 150.96 days for those on sham. In addition, continued treatment with the therapy showed a lower rate of brain atrophy than that observed in the sham arm during the randomized controlled period and OLE. In terms of safety, there were no observed amyloid-related imaging abnormalities or serious adverse events for treated patients.
Brent Vaughan, chief executive officer at Cognito and presenter of the data, sat down with NeurologyLive® at the conference to discuss the gamma sensory stimulation device and its mechanism of action. In the interview, Vaughan provided perspective about how this device could be used in combination with other approved medications and why its safety profile allows for further continued development. Furthermore, he spoke on the origins of the device and how it can be adjusted throughout treatment.
Click here for more coverage of CTAD 2023.
REFERENCE
1. Kuang C, Hajos M, Konisky A, et al. Overture open-label extension data confirms safety, adherence and durability of treatment benefits over 18 months. Presented at: Clinical Trials on Alzheimer’s Disease (CTAD) conference; October 24-27, 2023. POSTER LP026
